Symbio Releases White Paper: “Atopic Dermatitis – Considerations for Clinical Trials”

The newest white paper in Symbio’s white paper series was recently released entitled, “Atopic Dermatitis: Considerations for Clinical Trials.” This paper explores the clinical research challenges involved in AD trials including lack of standardized rating scales, the need to enroll children and young people, and the impact of time of year and geographic region.

Atopic dermatitis (AD), often called eczema, is a common and often debilitating skin condition whose root cause remains unknown but is likely to be related to allergies and immune dysregulation. No curative treatment exists for this condition and management usually consists of topical corticosteroids. In more severe cases, topical calcineurin inhibitors, biologics or immunosuppressants may be necessary. Unless remission occurs, AD is a chronic disease and needs to be suppressed through medication and vigorous hygiene practices.

AD’s prevalence, lack of cure, and impact on life quality have driven continuous research and investment into novel therapies. Unless an extremely tolerable and efficacious treatment becomes available, this trend is likely to continue.

GET THE WHITE PAPER

Symbio Releases White Paper: “The Clinical State of Psoriasis”

Symbio has released their latest white paper “The Clinical State of Psoriasis” which aims to explain why biologics have become so popular and why their introduction has been so disruptive to classic topical drug studies.

Psoriasis is a common and often debilitating skin disease that affects millions of Americans each year. In the last few decades a variety of different pharmaceutical interventions have been brought to market with the intention of alleviating the suffering this ailment inflicts. These efforts have coalesced into two main classes of drugs: Topical medications and systemic treatments. These systemic, biologic treatments generally come from a newer class of drugs known as monoclonal antibodies, or MABs.

As the psoriasis market expands to include new systemic agents, clinical trials and their enrollment become increasingly complex. Due to the rise of treatment options such as biologics, topical psoriasis drugs have seen slow enrollment over the last decade

GET THE WHITE PAPER

Success for Symbio at the 2022 AAD Annual Meeting

Symbio and Dow Development Laboratories exhibited at the 2022 AAD Annual Meeting from March 25 to March 29 at the Boston Convention & Exhibition Center in Boston, MA. The event was a huge success for all. It was wonderful to see so many familiar faces and to make new connections.

View videos of AAD Annual Meeting at the Symbio Booth and our 20th Anniversary Dinner Celebration at SPIN.